Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Resflox - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Resflox

Approved

STANDARD

Resflox

Albert David Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: c4dad8979cb94df6
Company: Albert David Limited
Type: Standard

Approval Details

Approval Id: c4dad8979cb94df6
Drug Approval Philippines Name: Resflox
Product Name: Resflox
Registration Number: DRP-7928
Brand Name: Resflox
Generic Name: Levofloxacin
Dosage Form: Solution For Iv Infusion
Dosage Strength: 5mg/100mL
Manufacturer: Albert David Limited
Importer: Medethix Incorporated
Distributor: Medethix Incorporated
Issuance Date: 26 February 2023
Expiry Date: 24 July 2028
Pharmacologic Category: Antibacterial (Fluoroquinolone)
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

c4dad8979cb94df6

Type

Standard

Back to Philippines FDA Approvals